#USA #Neuros Medical #Altius System #Arden Hills #Thomas Tovello

Neuros Medical Appoints Thomas Tovello as Chief Financial Officer

Neuros Medical, a prominent name in medical device innovation, has made a significant move by appointing Thomas Tovello as its new Chief Financial Officer (CFO). This announcement comes as part of the company’s strategy to advance its groundbreaking product, the ALTIUS® System, designed to alleviate chronic post-amputation pain.

A Seasoned Executive with a Strong Background

Tovello joins Neuros Medical after a notable tenure at Edwards Lifesciences. His previous role at Endotronix saw him as the Senior Vice President of Finance and Administration. There, he played a crucial role in preparing the company for its acquisition by Edwards Lifesciences, further underlining his capabilities in managing transitions and high-stakes financial environments.

With a robust career in the med-tech and pharmaceutical sectors, Tovello is recognized for his expertise in driving strategic growth through mergers and acquisitions and capital formation. His proven ability to secure substantial funding and develop effective financial strategies positions him as an asset to Neuros Medical, particularly during this critical phase aimed at enhancing the reach of their revolutionary ALTIUS system.

Leadership Praise and Expectations

David Veino, the President and CEO of Neuros Medical, expressed confidence in Tovello's capabilities. Veino stated, “Tom is an outstanding addition to our leadership team. His extensive experience in growth-stage med-tech and his collaborative approach make him the right person to help us navigate our next chapter.” As the company seeks to expand the commercial adoption of the ALTIUS product, the addition of Tovello is seen as a strategic move to bolster financial management during this scaling phase.

The ALTIUS System Explained

The ALTIUS System is a patient-controlled platform that utilizes patented technology to mitigate the intense pain experienced by amputees. This system targets the underlying causes of post-amputation pain by interrupting pain signals transmitted from damaged peripheral nerves. By incorporating both a nerve cuff electrode and an implantable pulse generator, patients can initiate treatment sessions as needed, ensuring direct management of their pain.

Pending FDA approval, the ALTIUS System has gained recognition as the first device of its kind to offer on-demand relief specifically tailored for adults suffering from phantom and residual limb pain. This innovation addresses a critical gap in treatment options, which have primarily relied on opioids and other conventional methods.

A Mission-Driven Approach

With nearly two million amputees in the U.S. alone, the need for effective management of post-amputation pain is higher than ever. Many of these individuals suffer from phantom limb pain and residual limb pain, affecting up to 80% of amputees. Neuros Medical aims to tackle this serious issue head-on, striving to transform the lives of those affected through innovative solutions like the ALTIUS system.

With his extensive background, Tovello is excited about his new role, stating, “I am thrilled to join the Neuros Medical team at such a pivotal moment. The commitment to improving the quality of life for patients with chronic pain resonates deeply with me. I look forward to contributing to the operational excellence as we expand our market reach.”

As Thomas Tovello steps into his role, the expectations are high not just for financial growth but also for making a lasting impact on the communities and individuals Neuro Medical aims to serve. The future looks promising as the team remains committed to their mission of ensuring pain relief and enhancing the quality of life for amputees.